MDG1021

MDG1021 is a T cell receptor-engineered T cell (TCR-T) immunotherapy that targets a specific, immunogenic form of the minor histocompatibility antigen HA-1. This antigen is exclusively expressed on cells of the hematopoietic system. The therapy is designed for patients with relapsed or persistent hematologic malignancies after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In these patients, if their blood cells—including lymphoma or leukemic cells—express the immunogenic version of HA-1 and donor stem cells do not, MDG1021-modified TCR-T cells can selectively eradicate malignant blood cells while allowing donor stem cells to repopulate the patient’s blood-forming system. The drug was developed by Leiden University Medical Center and Medigene and later rights were transferred to Miltenyi Biomedicine. Clinical development included a Phase I trial to assess safety and feasibility; however, this trial was withdrawn before enrollment due to transfer of rights[1][3][6][7].

Other names

HA-1-specific T cell receptor therapyHA1-specific T cell receptor therapyHA 1-specific T cell receptor therapy